<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Genmab A/S

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Genmab A/S

    Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and pre-clinical product pipeline and three proprietary next generation antibody technologies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $1,100,000,000
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Jan G. J. van de Winkel, Ph.D.
    • FOUNDED
      1999
    • EMPLOYEES
      251-500
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Ultragenyx Pharmaceutical Inc.

    Ultragenyx Pharmaceutical Inc.

    Ultragenyx is a biopharmaceutical company committed to bringing to patients novel ...

    Ultragenyx is a biopharmaceutical company commi...

    Filing Type:    PU
    Forward Pharma A/S

    Forward Pharma A/S

    Forward Pharma A/S is a Danish biopharmaceutical company that commenced developmen...

    Forward Pharma A/S is a Danish biopharmaceutica...

    Filing Type:    PU
    Tyme Technologies, Inc.

    Tyme Technologies, Inc.

    Tyme Inc. is an emerging biotechnology company developing cancer therapeutics that...

    Tyme Inc. is an emerging biotechnology company ...

    Filing Type:    PU
    Global Cancer Technology, Inc

    Global Cancer Technology, Inc

    Global Cancer Technology (“GCT”) is an emerging medical technology company with nu...

    Global Cancer Technology (“GCT”) is an emerging...

    Amount Raised:    $82,711.00
    Fundraising Status:    EC
    Filing Type:    CF
    IMAC Holdings, Inc.

    IMAC Holdings, Inc.

    IMAC Holdings, Inc. owns or manages IMAC Regeneration Centers, which combine life ...

    IMAC Holdings, Inc. owns or manages IMAC Regene...

    Filing Type:    PU
    IGM Biosciences, Inc.

    IGM Biosciences, Inc.

    Headquartered in Mountain View, California, IGM Biosciences is a biotechnology com...

    Headquartered in Mountain View, California, IGM...

    Filing Type:    PU
    IGM Biosciences, Inc.

    IGM Biosciences, Inc.

    Headquartered in Mountain View, California, IGM Biosciences is a biotechnology com...

    Headquartered in Mountain View, California, IGM...

    Filing Type:    PU
    Immunomedics, Inc.

    Immunomedics, Inc.

    Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal a...

    Immunomedics is a clinical-stage biopharmaceuti...

    Filing Type:    PU
    BioLineRx Ltd.

    BioLineRx Ltd.

    BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The C...

    BioLineRx is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    CTI BioPharma Corp.

    CTI BioPharma Corp.

    CTI BioPharma is a biopharmaceutical company focused on the acquisition, developme...

    CTI BioPharma is a biopharmaceutical company fo...

    Filing Type:    PU
    Epizyme, Inc.

    Epizyme, Inc.

    Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigene...

    Epizyme, Inc. is a clinical stage biopharmaceut...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.